Sophie Wang Will Discuss Claim Drafting at IP Watchdog 2023 Life Sciences Masters

Sophie Wang will be a panelist for the session, "The Future of Claim Drafting after Amgen: How Much Disclosure is Enough to Support the Claims?" at the IP Watchdog 2023 Life Sciences Masters Conference on Tuesday, October 17, 2023.

The panel, taking place at 11:05 a.m. at the IP Watchdog Studios in Ashburn, Virginia, will discuss the Supreme Court and Federal Circuit’s ruling in Amgen, as well as other related decisions, including the recent decision Baxalta Inc. v. Genentech, Inc.  Among other things, the panel will tackle the following questions:

1.Does the Amgen decision categorically eliminate broad genus claims?

2. Does Amgen and related cases create heightened requirements, or merely state the same old historic enablement requirement?

3. What can and should patent practitioners do to satisfy the enablement requirement moving forward?  How many examples are necessary to fully enable an invention?

4. Are broad genus claims dead? What level of disclosure is required to adequately support broad genus claims?

5. What claiming strategies can and should be employed to fully and fairly protect biopharmaceutical innovations moving forward? Should practitioners be considering use of means-plus-function claiming?

Learn more about the 2023 IP Watchdog Life Sciences Masters Conference here.